Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Buying Stake In Korean Drug Company

by Jean-François Tremblay
May 17, 2010 | A version of this story appeared in Volume 88, Issue 20

GlaxoSmithKline will spend $110 million to acquire a 10% stake in South Korea’s largest drug company, Dong-A Pharmaceuticals. As part of their agreement, the companies will more actively promote selected products from both firms to general practitioners in South Korea. Dong-A markets a range of proprietary and generic drugs; the firm posted sales of $700 million last year. GSK notes that South Korea’s pharmaceutical market grew 14% annually from 2006 to 2008, and the firm expects 10% annual growth over the next three years.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.